

Appendix 8

Table of diverging views

FINAL NUMBER	ACRONYM	Academic (n=17)			Industry (n=5)			Non profit/ Cancer organisations (n=8)			Small to mid-size enterprises / Contract Research Organizations (n=4)			Regulatory (n=4)			Health technology assessment (n=2)			Patient representatives (n=1)			TOTAL		
		Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr
1	EstFrame1_GEN	17	0	100%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	1	1	50%	1	0	100%	40	1	98%
2	AnalSens1_GEN	17	0	100%	5	0	100%	6	2	75%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	39	2	95%
3	Anal2_RCT	17	0	100%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	40	1	98%
4	Pop1_RCT	17	0	100%	4	1	80%	6	2	75%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	38	3	93%
5	Pop2_RCT	16	1	94%	4	1	80%	8	0	100%	4	0	100%	2	2	50%	1	1	50%	1	0	100%	36	5	88%
6	ICEdisprog1_RCT	15	1	94%	5	0	100%	6	2	75%	4	0	100%	4	0	100%	1	1	50%	1	0	100%	36	4	90%
7	ICEprodev1_RCT	16	1	94%	4	1	80%	6	2	75%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	37	4	90%
8	ICEconc1_RCT	15	2	88%	4	1	80%	6	2	75%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	36	5	88%
9	ICEdisprog3_RCT	15	2	88%	3	2	60%	6	2	75%	4	0	100%	1	2	33%	2	0	100%	1	0	100%	32	8	80%
10	ICEprodev3_RCT	15	2	88%	5	0	100%	8	0	100%	4	0	100%	3	0	100%	2	0	100%	1	0	100%	38	2	95%
11	ICEconc3_RCT	15	2	88%	5	0	100%	7	1	88%	4	0	100%	3	0	100%	2	0	100%	1	0	100%	37	3	93%
12	ICEdisprog2_RCT	14	3	82%	2	3	40%	6	2	75%	4	0	100%	2	1	67%	2	0	100%	2	0	100%	30	10	75%
13	ICEprodev2_RCT	15	2	88%	5	0	100%	7	1	88%	4	0	100%	3	0	100%	2	0	100%	1	0	100%	37	3	93%
14	ICEconc2_RCT	15	2	88%	4	1	80%	7	1	88%	4	0	100%	3	0	100%	2	0	100%	1	0	100%	36	4	90%
15	ICEdisprog5_RCT	16	1	94%	4	1	80%	6	2	75%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	37	4	90%
16	ICEprodev5_RCT	16	1	94%	5	0	100%	6	2	75%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	38	3	93%
17	ICEconc5_RCT	16	1	94%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	39	2	95%

WP2/RCT*

FINAL NUMBER	ACRONYM	Academic (n=17)			Industry (n=5)			Non profit/ Cancer organisations (n=8)			Small to mid-size enterprises / Contract Research Organizations (n=4)			Regulatory (n=4)			Health technology assessment (n=2)			Patient representatives (n=1)			TOTAL		
		Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr
18	ICEdisprog4_RCT	16	1	94%	3	2	60%	7	1	88%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	37	4	90%
19	ICEprodev4_RCT	16	1	94%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	39	2	95%
20	ICEconc4_RCT	16	1	94%	4	1	80%	7	1	88%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	38	3	93%
21	AnalSens2_GEN	17	0	100%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	41	0	100%
22	ICEdeth1_RCT	14	3	82%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	38	3	93%
23	ICEdisc1_GEN	14	3	82%	5	0	100%	4	3	57%	2	0	100%	4	0	100%	2	0	100%	1	0	100%	32	6	84%
24	Psum4_RCT	17	0	100%	5	0	100%	7	0	100%	2	0	100%	3	1	75%	2	0	100%	1	0	100%	37	1	97%
25	Psum5_RCT	17	0	100%	5	0	100%	8	0	100%	4	0	100%	3	1	75%	2	0	100%	1	0	100%	40	1	98%
26	Psum6_RCT	13	4	76%	5	0	100%	6	1	86%	2	0	100%	3	1	75%	2	0	100%	1	0	100%	32	6	84%
27	Design3_GEN	16	1	94%	5	0	100%	7	1	88%	3	1	75%	4	0	100%	2	0	100%	1	0	100%	38	3	93%
28	Anal1_GEN	16	1	94%	5	0	100%	7	0	100%	2	0	100%	4	0	100%	4	0	100%	1	0	100%	37	1	97%
29	ICE3_RCT	12	5	71%	4	1	80%	6	1	86%	2	0	100%	2	2	50%	2	0	100%	1	0	100%	29	9	76%
30	Design4_GEN	17	0	100%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	40	1	98%
31	AnalMain5_GEN	17	0	100%	4	1	80%	6	1	86%	2	0	100%	3	1	75%	2	0	100%	1	0	100%	35	3	92%
32	PROvar2_RCT	14	3	82%	4	1	80%	6	1	86%	2	0	100%	3	1	75%	2	0	100%	1	0	100%	32	6	84%
33	AnalMain2_GEN	15	2	88%	5	0	100%	6	2	75%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	37	4	90%
34	AnalMain3_GEN	16	0	100%	4	1	80%	8	0	100%	4	0	100%	3	1	75%	2	0	100%	1	0	100%	38	2	95%
35	AnalMain4_GEN	14	2	88%	4	1	80%	7	0	100%	2	0	100%	3	1	75%	2	0	100%	1	0	100%	33	4	89%
36	Assump1_GEN	17	0	100%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	41	0	100%
37	AnalMain1_GEN	14	3	82%	4	1	80%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	37	4	90%
38	Psum3_GEN	17	0	100%	5	0	100%	7	0	100%	2	0	100%	3	0	100%	2	0	100%	1	0	100%	37	0	100%
39	Psum1_GEN	17	0	100%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	41	0	100%
40	Psum2_GEN	17	0	100%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	41	0	100%
41	AnalMain8_RCT	16	1	94%	5	0	100%	6	1	86%	2	0	100%	4	0	100%	2	0	100%	1	0	100%	36	2	95%
42	AnalMain7_GEN	16	0	100%	4	1	80%	6	2	75%	4	0	100%	3	0	100%	2	0	100%	1	0	100%	36	3	92%
43	AnalSens3_GEN	15	1	94%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	38	2	95%
44	AnalMain6_GEN	14	2	88%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	38	2	95%
45	Design1_GEN	16	0	100%	5	0	100%	8	0	100%	4	0	100%	3	1	75%	2	0	100%	1	0	100%	39	1	98%

FINAL NUMBER	ACRONYM	Academic (n=17)			Industry (n=5)			Non profit/ Cancer organisations (n=8)			Small to mid-size enterprises / Contract Research Organizations (n=4)			Regulatory (n=4)			Health technology assessment (n=2)			Patient representatives (n=1)			TOTAL								
		Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr						
46	Design2_GEN																														
47	AnalPres1_GEN																														
48	ICE1_GEN																														
49	ICE2_GEN																														
50	PROvar1_GEN																														
WP6/CMC																															
1	CMCselc2_GEN	15	2	88%	5	0	100%	7	1	89%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	38	3	93%
2	CMCimp6_GEN	16	1	94%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	39	2	95%
3	CMCimp1_GEN	17	0	100%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	40	1	98%
4	CMCimp5_GEN	16	1	94%	5	0	100%	8	0	100%	3	1	76%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	39	2	95%
5	CMCimp4_GEN	16	1	94%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	0	0	-	38	2	95%
6	CMCimp3_GEN	16	1	94%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	40	1	98%
7	CMCimp2_GEN	17	0	100%	4	1	80%	6	2	75%	4	0	100%	4	0	100%	3	0	100%	2	0	100%	2	0	100%	1	0	100%	37	3	93%
8	CMCimp7_GEN	17	0	100%	5	0	100%	7	0	100%	2	0	100%	3	1	75%	3	1	75%	2	0	100%	2	0	100%	1	0	100%	37	1	97%
9	CMCimp8_GEN	15	2	88%	5	0	100%	5	2	71%	2	0	100%	2	0	100%	4	0	100%	1	1	50%	1	1	50%	1	0	100%	33	5	87%
10	CMCimp9_RCT	16	0	100%	5	0	100%	5	1	83%	2	0	100%	2	0	100%	3	1	75%	2	0	100%	2	0	100%	1	0	100%	34	2	94%
11	CMCselc7_GEN	17	0	100%	4	1	80%	6	2	75%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	38	3	93%
12	CMCselc1_GEN	14	3	82%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	38	3	93%
13	CMCselc5_GEN	15	2	88%	5	0	100%	5	2	71%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	36	4	90%
14	CMCselc3_GEN	16	1	94%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	40	1	98%
15	CMCselc4_GEN	17	0	100%	5	0	100%	6	1	86%	2	0	100%	2	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	37	1	97%
16	CMCimp14_GEN	16	1	94%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	39	2	95%
17	CMCimp13_GEN	17	0	100%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	41	0	100%
18	CMCrep1_GEN	17	0	100%	5	0	100%	6	2	75%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	39	2	95%
19	CMCimp10_GEN	17	0	100%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	41	0	100%
20	CMCrep3_GEN	15	2	88%	4	1	80%	6	1	86%	1	1	50%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	33	5	87%
21	CMCrep4_GEN	17	0	100%	5	0	100%	6	1	86%	1	1	50%	4	0	100%	4	0	100%	2	0	100%	2	0	100%	1	0	100%	36	2	95%

FINAL NUMBER	ACRONYM	Academic (n=17)			Industry (n=5)			Non profit/ Cancer organisations (n=8)			Small to mid-size enterprises / Contract Research Organizations (n=4)			Regulatory (n=4)			Health technology assessment (n=2)			Patient representatives (n=1)			TOTAL		
		Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr
22	CMCrep5_GEN	16	1	94%	5	0	100%	6	1	86%	2	0	100%	4	0	100%	2	0	100%	1	0	100%	36	2	95%
23	CMCimp11_GEN	17	0	100%	4	1	80%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	40	1	98%
24	CMCrep6_GEN	17	0	100%	4	1	80%	6	2	75%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	38	3	93%
25	CMCsel6_GEN	13	2	87%	4	1	80%	4	4	50%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	32	7	82%
26	CMCrep2_GEN	16	0	100%	4	1	80%	6	2	75%	4	0	100%	3	1	75%	2	0	100%	1	0	100%	36	4	90%
27	CMCimp12_GEN	14	2	88%	4	1	80%	6	2	75%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	35	5	88%
WP3/SAT																									
1	EstFrame2_SAT	17	0	100%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	4	0	100%	41	0	100%
2	EstFrame3_SAT	17	0	100%	4	1	80%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	40	1	98%
3	EstFrame4_SAT	12	5	71%	5	0	100%	4	4	50%	4	0	100%	2	1	67%	0	2	0%	1	0	100%	28	12	70%
4	EstFrame5_SAT	13	4	76%	5	0	100%	6	2	75%	4	0	100%	3	1	75%	2	0	100%	1	0	100%	34	7	83%
5	EstFrame6_SAT	13	4	76%	4	1	80%	6	2	75%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	34	7	83%
6	Pop3_SAT	15	2	88%	5	0	100%	5	3	63%	4	0	100%	4	0	100%	1	1	50%	1	0	100%	35	6	85%
7	AnalPres3_SAT	17	0	100%	5	0	100%	4	4	50%	4	0	100%	4	0	100%	1	1	50%	1	0	100%	36	5	88%
8	AnalMain9_SAT	16	1	94%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	1	1	50%	1	0	100%	39	2	95%
9	ICEdeath3_SAT	10	7	59%	5	0	100%	4	4	50%	4	0	100%	2	1	67%	2	0	100%	1	0	100%	28	12	70%
10	ICEdeath4_SAT	12	5	71%	4	1	80%	4	4	50%	3	1	75%	3	1	75%	2	0	100%	1	0	100%	29	12	71%
11	Design2_GEN	17	0	100%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	1	1	50%	1	0	100%	39	2	95%
12	ICE5_SAT	14	3	82%	3	2	60%	7	1	88%	4	0	100%	3	1	75%	2	0	100%	1	0	100%	34	7	83%
13	ExComp1_SAT	13	4	76%	5	0	100%	6	2	75%	3	1	75%	2	0	100%	1	0	100%	1	0	100%	31	7	82%
14	ExComp2_SAT	12	5	71%	5	0	100%	6	2	75%	4	0	100%	3	0	100%	1	0	100%	1	0	100%	32	7	82%
15	AnalPres2_SAT	17	0	100%	5	0	100%	7	1	88%	3	1	75%	3	1	75%	2	0	100%	1	0	100%	38	3	93%
16	ICEdeath2_SAT	14	3	82%	4	1	80%	4	4	50%	4	0	100%	3	1	75%	1	1	50%	1	0	100%	31	10	76%
17	Assump2_SAT	14	3	82%	5	0	100%	6	1	86%	1	1	50%	3	1	75%	2	0	100%	1	0	100%	32	6	84%
18	AnalPres1_GEN	17	0	100%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	1	0	100%	1	0	100%	39	1	98%
19	ICE1_GEN	15	2	88%	5	0	100%	5	2	71%	2	0	100%	3	0	100%	1	1	50%	1	0	100%	32	5	86%
20	ICE2_GEN	14	3	82%	5	0	100%	4	3	57%	2	0	100%	3	1	75%	1	1	50%	1	0	100%	30	8	79%

FINAL NUMBER	ACRONYM	Academic (n=17)			Industry (n=5)			Non profit/ Cancer organisations (n=8)			Small to mid-size enterprises / Contract Research Organizations (n=4)			Regulatory (n=4)			Health technology assessment (n=2)			Patient representatives (n=1)			TOTAL		
		Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr
21	ICE4_SAT	14	3	82%	5	0	100%	3	4	43%	2	0	100%	2	2	50%	1	1	50%	1	0	100%	28	10	74%
22	PROvar1_GEN	16	1	94%	5	0	100%	6	2	75%	3	1	75%	3	1	75%	2	0	100%	1	0	100%	36	5	88%
23	Design1_GEN	16	0	100%	5	0	100%	6	2	75%	4	0	100%	3	1	75%	2	0	100%	1	0	100%	37	3	93%
24	AnalSens4_SAT	16	0	100%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	40	0	100%
25	AnalMain7_GEN	14	0	100%	5	0	100%	8	0	100%	3	0	100%	3	1	75%	2	0	100%	1	0	100%	36	1	97%
26	AnalSens3_GEN	15	1	94%	4	1	80%	7	1	88%	4	0	100%	3	1	75%	2	0	100%	1	0	100%	36	4	90%
27	EstFrame1_GEN	Adapted without voting																							
28	AnalSens1_GEN	Adapted without voting																							
29	AnalSens2_GEN	Adapted without voting																							
30	ICEdisc1_GEN	Adapted without voting																							
31	Design3_GEN	Adapted without voting																							
32	Anal1_GEN	Adapted without voting																							
33	Design4_GEN	Adapted without voting																							
34	AnalMain5_GEN	Adapted without voting																							
35	AnalMain2_GEN	Adapted without voting																							
36	AnalMain3_GEN	Adapted without voting																							
37	AnalMain4_GEN	Adapted without voting																							
38	Assump1_GEN	Adapted without voting																							
39	AnalMain1_GEN	Adapted without voting																							
40	Psum3_GEN	Adapted without voting																							
41	Psum1_GEN	Adapted without voting																							
42	Psum2_GEN	Adapted without voting																							
43	AnalMain6_GEN	Adapted without voting																							
WP4/Graphs																									
1	VizSci1_GEN	16	1	94%	4	1	80%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	39	2	95%
2	VizSci11_GEN	16	1	94%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	39	2	95%
3	VizSci3_GEN	17	0	100%	4	1	80%	6	2	75%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	38	3	93%

FINAL NUMBER	ACRONYM	Academic (n=17)			Industry (n=5)			Non profit/ Cancer organisations (n=8)			Small to mid-size enterprises / Contract Research Organizations (n=4)			Regulatory (n=4)			Health technology assessment (n=2)			Patient representatives (n=1)			TOTAL		
		Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr	Agr	Disagr	%Agr
4	VizSci2_GEN	17	0	100%	5	0	100%	7	0	100%	2	0	100%	4	0	100%	2	0	100%	1	0	100%	38	0	100%
5	VizSci6_GEN	17	0	100%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	41	0	100%
6	VizSci7_GEN	16	1	94%	4	1	80%	5	2	71%	2	0	100%	4	0	100%	2	0	100%	1	0	100%	34	4	89%
7	VizSci8_GEN	17	0	100%	5	0	100%	7	0	100%	2	0	100%	4	0	100%	2	0	100%	1	0	100%	38	0	100%
8	VizSci5_GEN	16	1	94%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	39	2	95%
9	VizSci4_GEN	17	0	100%	5	0	100%	7	1	88%	4	0	100%	4	0	100%	2	0	100%	0	0	-	39	1	98%
10	VizSci9_GEN	16	1	94%	5	0	100%	7	0	100%	2	0	100%	4	0	100%	2	0	100%	1	0	100%	37	1	97%
11	VizSci10_GEN	17	0	100%	5	0	100%	8	0	100%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	41	0	100%
12	VizSci13_GEN	17	0	100%	4	1	80%	6	2	75%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	38	3	93%
13	VizSciType1_GEN	15	2	88%	5	0	100%	7	0	100%	2	0	100%	3	1	75%	1	1	50%	1	0	100%	34	4	89%
14	VizSciType2_GEN	14	3	82%	4	1	80%	7	0	100%	2	0	100%	3	1	75%	1	1	50%	1	0	100%	32	6	84%
15	VizSciType3_GEN	15	2	88%	4	1	80%	7	1	88%	4	0	100%	4	0	100%	2	0	100%	1	0	100%	37	4	90%
16	VizSciType4_GEN	16	1	94%	5	0	100%	6	1	86%	2	0	100%	2	2	50%	2	0	100%	1	0	100%	34	4	89%
17	VizSci12_GEN	15	1	94%	5	0	100%	5	3	63%	4	0	100%	3	1	75%	2	0	100%	1	0	100%	35	5	88%
18	VizPlain1_GEN	17	0	100%	5	0	100%	7	1	88%	4	0	100%	3	1	75%	2	0	100%	1	0	100%	39	2	95%
19	VizPlain2_GEN	14	3	82%	5	0	100%	7	0	100%	2	0	100%	4	0	100%	2	0	100%	1	0	100%	35	3	92%
20	VizPlain3_GEN	17	0	100%	5	0	100%	7	0	100%	2	0	100%	4	0	100%	2	0	100%	1	0	100%	38	0	100%
21	VizPlain4_GEN	17	0	100%	5	0	100%	6	1	86%	2	0	100%	4	0	100%	1	1	50%	1	0	100%	36	2	95%
22	VizPlainType1_GEN	16	1	94%	5	0	100%	7	0	100%	2	0	100%	3	1	75%	1	1	50%	1	0	100%	35	3	92%
23	VizPlainType2_GEN	14	3	82%	4	1	80%	6	1	86%	2	0	100%	3	1	75%	2	0	100%	1	0	100%	32	6	84%
24	VizPlainType3_GEN	17	0	100%	5	0	100%	7	0	100%	2	0	100%	3	1	75%	0	2	0%	1	0	100%	35	3	92%
25	VizPlainType4_GEN	15	2	88%	4	1	80%	8	0	100%	4	0	100%	3	1	75%	2	0	100%	1	0	100%	37	4	90%
WP8/Patients																									
1	VizPlainType5_GEN	14	0	100%	5	0	100%	8	0	100%	3	0	100%	4	0	100%	1	0	100%	1	0	100%	36	0	100%

